Nachrichten zur CROSSJECT S.A. Aktie

Crossject announces its eligibility for France’s PEA-PME investment scheme

Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265;…

Crossject announces its eligibility for France’s PEA-PME investment scheme

Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations…

Crossject reports financial results and business highlights for the first six months of 2024

Dijon, France, September 23, 2024 18:00 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning…

Crossject achieves key ZEPIZURE® manufacturing milestone

Dijon, France, July 18, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases…

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Dijon, France 26 June, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development…

Crossject announces highly successful closing of its €8 million rights offering

Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April…

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy

…

Crossject reports audited financial results for 2023

Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations…